Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Rapamune (sirolimus)oral solution and tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2010

 

Summary View

 

WARNINGS AND PRECAUTIONS

Fluid Accumulation and Wound Healing
  • ascites
Assay for Sirolimus Therapeutic Drug Monitoring
  • Currently in clinical practice, sirolimus whole blood concentrations are being measured by various chromatographic and immunoassay methodologies. Patient sample concentration values from different assays may not be interchangeable

ADVERSE REACTIONS

  • Cardiovascular: and fluid accumulation
  • Digestive System: Ascites

 

-
-